Distribution and antifungal susceptibility of Candida species isolated from clinical samples in southern Brazil
DOI:
https://doi.org/10.1590/s2175-97902022e20727Keywords:
Vulvovaginal candidiasis, Candida albicans, Antifungal agents, Antifungal Drug resistance, AzolesAbstract
Invasive infections caused by Candida species have been strongly associated with poor prognosis and high resistance rates to some antifungals. This study aimed to identify Candida species isolated from different anatomical sites and to describe their susceptibility profile to antifungals. Ninety-four clinical isolates of Candida were obtained from a Medical Laboratory of Santa Catarina/Brazil. Species identification was performed by MALDI-TOF MS. Susceptibility assays were performed as described by Clinical Laboratory Standard Institute (CLSI) microboth method. Among the analyzed samples, C. albicans was the pathogen most incident (59.9%) followed by C. parapsilosis complex (14.9%), C. glabrata complex (8.5%), and C. tropicalis (6.3%). 37 Candida strains were isolated from vaginal content (39.3%), 21 from the nail (22.4%), 8 from tracheal aspirates (8.5%), and 7 from urine (7.4%). Together, the Candida isolates presented decreased susceptibility to azole drugs, mainly to fluconazole and itraconazole. Amphotericin B showed sensibility in 95.7% of samples analyzed. Previous knowledge about etiology and antifungal susceptibility becomes indispensable to conduct an efficient treatment.
Downloads
References
Alvares CA, Svidzinski TIE, Consolaro MEL. Vulvovaginal candidiasis: predisposing factors of the host and virulence of yeasts. J Bras Patol Med Lab. 2007;43(5):319-327.
Antinori S, Milazzo L, Sollima S, Galli M. Candidemia and invasive candidiasis in adults: A narrative review. Eur J Intern Med. 2016;34:21-28.
Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and Mechanisms of Antifungal Resistance. Antibiotics (Basel). 2020;9(6):312.
Beardsley J, Halliday CL, Chen SC, Sorrell TC. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018;13(10):1175-1191.
Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Martinez AMB, Mendes JF, et al. Prevalence of Candida spp. In cervical-aginal samples and the in vitro susceptibility of isolates. Braz J Microbiol. 2017;48(1):145-150.
Carvalho MHGF, Ramos LS, Barbedo LS. First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes. Mem Inst Oswaldo Cruz. 2016;111(1):51-58.
Chang Y, Yu S, Heitman J, Wellington M, Chen Y. New facets of antifungal therapy. Virulence. 2017;8(2):222-236.
Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 3rd edn. CLSI Document M27-A3. Clinical Laboratory Standards Institute, Wayne, PA, USA, 2008.
Demitto FO, Do Amaral RCR, Biasi RP, Guilhermetti E, Svidzinski TIE, Baeza LC. Susceptibility to in vitro antifungals of Candida spp. in patients of the Regional University Hospital of Maringá-PR. J Bras Patol Med Lab . 2012;48(5):315-321.
Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):1-9.
Ellah ANH, Abdel-Aleem JÁ, Abdo MN, Abou-Ghadir OF, Zahran KM, Hetta HF. Efficacy of ketoconazole gel-flakes in treatment of vaginal candidiasis: Formulation, in vitro and clinical evaluation. Int J Pharm. 2019;567:118472.
Fay VS, Gregianini TS, Veiga ABG, Gonçalves SMB, Rodrigues DM, Bonamigo RR. A 12-year study of fungal infections in Rio Grande do Sul, Southern Brazil. Rev Iberoam Micol. 2019;36(2):55-60.
Firacative C. Invasive fungal disease in humans: are we aware of the real impact? Mem Inst Oswaldo Cruz [online]. 2020;115:e200430.
Ferreira EG, Yatsuda F, Pini M. Implications of the presence of yeasts in tracheobronchial secretions of critically ill intubated patients. EXCLI J. 2019;9(18):801-811.
Fich F, Abarzúa-Araya A, Pérez M, Nauhm Y, León E. Candida parapsilosis and Candida guillermondii: emerging pathogens in nail candidiasis. Indian J Dermatol. 2014;59(1):24-29.
Fuentefria AM, Pippi B, Dalla LDF, Donato KK, Andrade SF. Antifungals discovery: an insight into new strategies to combat antifungal resistance. Lett Appl Microbiol. 2018;66(1):2-13.
Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990.
Lirio J, Giraldo PC, Amaral RL, Sarmento ACA, Costa APFC, Gonçalves AK. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. BMJ Open. 2019;9(11):e027489.
Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med. 2020;46(11):2001-2014.
Marchaim D, Lemanek L, Bheemreddy S, Kaye K, Sobel J. Fluconazole-resistent Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407-14.
Mattos K, Rodrigues LC, Oliveira KMP, Diniz PF, Marques LI, Araujo AA, et al. Variability in the clinical distributions of Candida species and the emergence of azole-resistant non-Candida albicans species in public hospitals in the Midwest region of Brazil. Rev Soc Bras Med Trop. 2017;50(6):843-847.
Mushi MF, Mmole A, Mshana SE. Candida vaginitis among symptomatic pregnant women attending antenatal clinics in Mwanza, Tanzania. BMC Res Notes. 2019;12(1):775.
Nett JE. Putative Role of -1,3 Glucans in Candida albicans biofilme resistance. Antimicrob Agents Chemother. 2007;51(2):510-520.
Neves-Junior A, Pinto ACC, Rocha DAS, De Sá LFR, Junqueira ML, Ferreira Pereira, A. Prevalence and fluconazole susceptibility profile of Candida spp. Clinical isolates in a Brazilian Tertiary Hospital in Minas Gerais, Brazil. An Acad Bras Cienc. 2015;87(2):1349-1359.
Nucci M, Queiroz-telles F, Tobón AM, Restrepo A, Colombo A. L. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis. 2010;51(5):561-570.
Nunes EB, Monteiro JCMS, Nunes NB, Paes ALV. Profile of sensitivity of the genus Candida to antifungals in a reference hospital in the northern region of Brazil. Rev Pan-Amaz Saude. 2011;2(4):23-30.
O’Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe. 2020;1(5):193-194.
Odabasi Z, Mert A. Candida urinary tract infections in adults. World J Urol. 2020;38(11):2699-2707.
Pais P, Califórnia R, Galocha M, Viana R, Ola M, Cavalheiro M, et al. Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability. Antimicrob Agents Chemother . 2020;64(9):e00554-20.
Peron IH, Lima RF, Lopes BAF, Nagasako CK, Lyra L, Moretti ML, et al. Resistance Surveillance in Candida albicans: a five-year antifungal susceptibility evaluation in a Brazilian university hospital. PLoS One. 2016;11(7):e0158126.
Sadeghi L, Ebrahimi-Rad H, Mousavi SF, Shams-Ghahfarokhi H, Razzaghi-Abyaneh H. Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile. J Mycol Med. 2018;28(1):51-58.
Santana DP, Ribeiro EL, Menezes ACS, Naves PLF. New approaches to the virulence factors of Candida albicans Rev Cienc Med Biol. 2013;12(2):229-233.
Sardi JC, Scorzoni L, Bernardi T, Fusco S AM, Mendes Gianini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(1):10-24.
Sasikala G, Udayarsi B. Speciation and antifungal susceptibility profiles of Candida isolates from vaginitis patients attending STD Clinic at a Tertiary Care Hospital. J NTR Univ Health Sci. 2018;77(2):94-7.
Silva RB, Neves RP, Hinrichsen SL, Lima-Neto RG. Candidemia in a public hospital in Northeastern Brazil: Epidemiological features and risk factors in critically. Rev Iberoam Micol . 2019;36(4):181-185.
Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. QJM. 2016;109(5):325-329.
Wang D, Zhang W, Ju JX, Wang LJ, Huang RY, Xu YF, et al. Gender differences in acute toxicity, toxicokinetic and tissue distribution of amphotericin B liposomes in rats. Toxicol Lett. 2021;338(1):78-84.
Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. J Fungi (Basel). 2020;25:6 (1):27.
Zeng ZR, Tian G, Ding YH, Yang K, Liu JB, Deng J. Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China. BMC Infect Dis. 2019;9(1):939.
Zida A, Yacouba A, Bamba S, Sangare I, Sawadogo M, Guiguemede T, et al. Invitro susceptibility of Candidaalbicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso). J Mycol Med . 2017;27(4):469-475.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
